<DOC>
	<DOCNO>NCT00002274</DOCNO>
	<brief_summary>The objective open-label study regimen make didanosine ( ddI ) available patient AIDS clinically deteriorate zidovudine ( AZT ) enter Phase II ddI program due protocol exclusion geographic location .</brief_summary>
	<brief_title>A Study ddI Patients With AIDS Who Become Sicker While Taking Zidovudine</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Leukoencephalopathies</mesh_term>
	<mesh_term>Leukoencephalopathy , Progressive Multifocal</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Concurrent medication treatment complication AIDS allow . Aerosolized pentamidine . Phenytoin , caution . Note : Extreme caution exercise use didanosine ( ddI ) patient receive concurrent therapy , particularly receive nucleoside ( e.g. , ganciclovir ) , drug toxicity similar observe ddI ( list include concomitant medication section protocol ) , drug significant toxicity , include many drug use treatment major opportunistic infection . Patients must : Not suitable entry ddI phase II study reason inclusion exclusion criterion reason geographic location . Able provide sign informed consent ( parent/guardian appropriate ) . Available monthly followup take ddI . Meet required baseline laboratory value within 14 day prior initial drug dosing . Note : Extreme caution exercise use ddI patient receive concomitant therapy , particularly receive nucleoside ( e.g. , ganciclovir ) , drug toxicity similar observe ddI ( list include concomitant medication section protocol ) , drug significant toxicity , include many drug use treatment major opportunistic infection . Caution also exercise patient intractable diarrhea patient follow lowsodium diet . Physicians care patient must perform clinical laboratory evaluation every 710 day first 2 month ddI therapy . Should adverse effect severity detect period intensive clinical laboratory monitoring , physician must call BristolMyers Squibb ( 18006627999 ) . If patient continue ddI therapy , BristolMyers Squibb require submission followup adverse experience report form every 10 day . Although data available fully assess risk associate use ddI highrisk patient ( example , patient preexist disorder body system know adversely affected ddI , particularly history peripheral neuropathy , pancreatitis , seizure disorder , cardiac abnormality , gout , significant elevation liver function test result ) , patient must clinical laboratory evaluation perform every 10 day result submit BristolMyers Squibb case report form provide . Exclusion Criteria Coexisting Condition : Patients one follow criterion exclude : Received therapy precede 15 day antiretroviral except zidovudine ( AZT ) . Taking AZT concomitantly . Acute pancreatitis . Poorly controlled seizure disorder . Taking phenytoin concomitantly . Grade B great peripheral neuropathy . Concurrent Medication : Excluded : Zidovudine ( AZT ) . Patients one follow criterion exclude : Received therapy precede 15 day antiretroviral except zidovudine ( AZT ) . Taking AZT concomitantly . Taking phenytoin concomitantly . Acute pancreatitis . Poorly controlled seizure disorder . Grade B great peripheral neuropathy . Prior Medication : Excluded within 15 day study entry : Any antiretroviral except zidovudine ( AZT ) . Required : Zidovudine ( AZT ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>